

Tao Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/595652/publications.pdf>

Version: 2024-02-01

123
papers

19,707
citations

70961

41
h-index

32761

100
g-index

127
all docs

127
docs citations

127
times ranked

39872
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in therapeutic agents targeting quiescent cancer cells. , 2022, 1, .		6
2	Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells. Discover Oncology, 2022, 13, .	0.8	6
3	YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of <i>FZD7</i> . Cancer Research, 2021, 81, 2651-2665.	0.4	150
4	Targeted Therapy of <i>TERT</i> -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. Clinical Cancer Research, 2021, 27, 1438-1451.	3.2	20
5	NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma. Cellular and Molecular Life Sciences, 2021, 78, 2213-2230.	2.4	39
6	The RNA helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. Molecular Oncology, 2021, 15, 1162-1179.	2.1	12
7	An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability. Nature Communications, 2021, 12, 1881.	5.8	31
8	A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. Oncogene, 2021, 40, 2367-2381.	2.6	13
9	The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance. Cancer Research, 2021, 81, 3431-3440.	0.4	129
10	The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis. Nature Communications, 2021, 12, 3734.	5.8	33
11	Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. Briefings in Functional Genomics, 2021, 20, 289-303.	1.3	16
12	Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells. Theranostics, 2021, 11, 9605-9622.	4.6	14
13	Transcriptional regulation of G2/M regulatory proteins and perturbation of G2/M Cell cycle transition by a traditional Chinese medicine recipe. Journal of Ethnopharmacology, 2020, 251, 112526.	2.0	16
14	Sequencing dropout-and-batch effect normalization for single-cell mRNA profiles: a survey and comparative analysis. Briefings in Bioinformatics, 2020, 22, .	3.2	4
15	c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. Nature Communications, 2020, 11, 4980.	5.8	70
16	Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma. International Journal of Molecular Sciences, 2020, 21, 5098.	1.8	16
17	LVA influenced the SIRT1-miR-27a-p53-MAD2-MMP1/COL1/BCL2 axis in human skin primary fibroblasts. Journal of Cellular and Molecular Medicine, 2020, 24, 10027-10041.	1.6	7
18	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. Cancer Cell, 2020, 38, 263-278.e6.	7.7	59

#	ARTICLE	IF	CITATIONS
19	Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against <i>MYCN</i> -amplified neuroblastoma. <i>International Journal of Cancer</i> , 2020, 147, 1928-1938.	2.3	28
20	CPF impedes cell cycle re-entry of quiescent lung cancer cells through transcriptional suppression of FACT and <i>MYC</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2229-2239.	1.6	11
21	Abstract 5721: The super-enhancer driven long noncoding RNA <i>lncNB</i> promotes neuroblastoma tumorigenesis. , 2020, , .		0
22	<i>JMJD6</i> is a tumorigenic factor and therapeutic target in neuroblastoma. <i>Nature Communications</i> , 2019, 10, 3319.	5.8	63
23	The long noncoding RNA <i>lncNB1</i> promotes tumorigenesis by interacting with ribosomal protein RPL35. <i>Nature Communications</i> , 2019, 10, 5026.	5.8	67
24	The Histone Demethylase <i>NO66</i> Induces Glioma Cell Proliferation. <i>Anticancer Research</i> , 2019, 39, 6007-6014.	0.5	5
25	The Critical Role of RNA m6A Methylation in Cancer. <i>Cancer Research</i> , 2019, 79, 1285-1292.	0.4	505
26	Drugging <i>MYCN</i> Oncogenic Signaling through the <i>MYCN-PA2G4</i> Binding Interface. <i>Cancer Research</i> , 2019, 79, 5652-5667.	0.4	24
27	<i>lncRNA REG1CP</i> promotes tumorigenesis through an enhancer complex to recruit FANCD1 helicase for <i>REG3A</i> transcription. <i>Nature Communications</i> , 2019, 10, 5334.	5.8	43
28	Association of GDF-15 and Syntax Score in Patient with Acute Myocardial Infarction. <i>Cardiovascular Therapeutics</i> , 2019, 2019, 1-6.	1.1	4
29	The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells. <i>International Journal of Cancer</i> , 2019, 145, 164-178.	2.3	20
30	<i>JMJD1C</i> -mediated metabolic dysregulation contributes to <i>HOXA9</i> -dependent leukemogenesis. <i>Leukemia</i> , 2019, 33, 1400-1410.	3.3	31
31	Abstract 3659: <i>Alyref</i> is a novel binding partner and co-factor for <i>MYCN</i> -driven oncogenesis in neuroblastoma. , 2019, , .		0
32	Abstract 5209: Efficacious targeting of <i>TERT</i> oncogene rearrangement with BET bromodomain inhibitor and proteasome inhibitor combination therapy. , 2019, , .		0
33	Abstract 4504: <i>MILIP</i> is a pan cancer-associated long noncoding RNA that links <i>MYC</i> to inactivation of <i>p53</i> . , 2019, , .		0
34	Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies <i>miR-204</i> as a Direct Inhibitor of <i>MYCN</i> . <i>Cancer Research</i> , 2018, 78, 3122-3134.	0.4	48
35	Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma. <i>Cell Cycle</i> , 2018, 17, 749-758.	1.3	13
36	Cooperativity of <i>HOXA5</i> and <i>STAT3</i> Is Critical for <i>HDAC8</i> Inhibition-Mediated Transcriptional Activation of <i>PD-L1</i> in Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2018, 138, 922-932.	0.3	26

#	ARTICLE	IF	CITATIONS
37	ACTN4 regulates the stability of RIPK1 in melanoma. <i>Oncogene</i> , 2018, 37, 4033-4045.	2.6	20
38	Recognition of CRISPR/Cas9 off-target sites through ensemble learning of uneven mismatch distributions. <i>Bioinformatics</i> , 2018, 34, i757-i765.	1.8	38
39	A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence. <i>Cancer Research</i> , 2018, 78, 6666-6679.	0.4	29
40	Abstract 2523: Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells. <i>Cancer Research</i> , 2018, 78, 2523-2523.	0.4	1
41	Abstract 52: A genomic editing approach for purification of viable quiescent cancer cells. , 2018, , .		0
42	The regulatory role of long noncoding RNAs in cancer. <i>Cancer Letters</i> , 2017, 391, 12-19.	3.2	94
43	The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. <i>Cancer Research</i> , 2017, 77, 2522-2533.	0.4	59
44	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 4462-4472.	3.2	85
45	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. <i>Cancer Research</i> , 2017, 77, 971-981.	0.4	90
46	Up-regulation of LYAR blocks Myc-induced cell death. <i>Cell Cycle</i> , 2017, 16, 1857-1858.	1.3	2
47	Upregulation of LYAR induces neuroblastoma cell proliferation and survival. <i>Cell Death and Differentiation</i> , 2017, 24, 1645-1654.	5.0	15
48	Chromosome preference of disease genes and vectorization for the prediction of non-coding disease genes. <i>Oncotarget</i> , 2017, 8, 78901-78916.	0.8	2
49	Abstract LB-080: The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription. , 2017, , .		1
50	NCYM is upregulated by IncUSMycN and modulates N-Myc expression. <i>International Journal of Oncology</i> , 2016, 49, 2464-2470.	1.4	21
51	Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. <i>Cell Death and Disease</i> , 2016, 7, e2252-e2252.	2.7	33
52	Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1745-1748.	3.3	9
53	High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. <i>Cancer Letters</i> , 2016, 374, 315-323.	3.2	42
54	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. <i>Clinical Cancer Research</i> , 2016, 22, 2534-2544.	3.2	100

#	ARTICLE	IF	CITATIONS
55	INPP4B is an oncogenic regulator in human colon cancer. <i>Oncogene</i> , 2016, 35, 3049-3061.	2.6	52
56	Abstract 2450: MYCN and TFAP4 promote neuroblastoma malignancy by cooperating in the regulation a subset of target genes involved in cancer cell growth and metastasis. , 2016, , .		2
57	Abstract 2664: Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA. <i>Cancer Research</i> , 2016, 76, 2664-2664.	0.4	1
58	MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. <i>Oncotarget</i> , 2016, 7, 54937-54951.	0.8	20
59	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. <i>Oncotarget</i> , 2016, 7, 79217-79232.	0.8	17
60	The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. <i>Oncotarget</i> , 2016, 7, 8663-8675.	0.8	97
61	Abstract B13: Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA. , 2016, , .		0
62	Abstract LB-149: LYAR promotes cell proliferation by repressing CHAC1 expression in neuroblastoma. , 2016, , .		0
63	Connecting rules from paired miRNA and mRNA expression data sets of HCV patients to detect both inverse and positive regulatory relationships. <i>BMC Genomics</i> , 2015, 16, S11.	1.2	21
64	An inverse relationship between serum macrophage inhibitory cytokine-1 levels and brain white matter integrity in community-dwelling older individuals. <i>Psychoneuroendocrinology</i> , 2015, 62, 80-88.	1.3	13
65	<i>IGF2BP1</i> Harbors Prognostic Significance by Gene Gain and Diverse Expression in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1285-1293.	0.8	55
66	Thymosin α 24 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. <i>Molecular Oncology</i> , 2015, 9, 1484-1500.	2.1	17
67	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <i>Science Translational Medicine</i> , 2015, 7, 312ra176.	5.8	120
68	WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. <i>Cancer Research</i> , 2015, 75, 5143-5154.	0.4	88
69	Abstract 146: The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells. <i>Cancer Research</i> , 2015, 75, 146-146.	0.4	2
70	The Relationship of Serum Macrophage Inhibitory Cytokine α 1 Levels with Gray Matter Volumes in Community-Dwelling Older Individuals. <i>PLoS ONE</i> , 2015, 10, e0123399.	1.1	16
71	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. <i>Oncotarget</i> , 2015, 6, 39891-39907.	0.8	40
72	Abstract 4718: Inositol polyphosphate 4-phosphatase II activates PI3K/SGK3 signaling to promote proliferation of human melanoma cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract 962: PA2G4 predicts poor prognosis in neuroblastoma patients and promotes neuroblastoma progression by enhancing MYCN protein stability. , 2015, , .		0
74	Abstract PR09: MYCN and is a therapeutic target in neuroblastoma. , 2015, , .		0
75	The prenatal origins of cancer. Nature Reviews Cancer, 2014, 14, 277-289.	12.8	201
76	Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. Oncogene, 2014, 33, 2987-2994.	2.6	36
77	Effects of a Novel Long Noncoding RNA, IncUSMycN, on N-Myc Expression and Neuroblastoma Progression. Journal of the National Cancer Institute, 2014, 106, .	3.0	98
78	Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. Journal of Proteomics, 2014, 96, 1-12.	1.2	19
79	Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein. Oncology Reports, 2014, 31, 1935-1939.	1.2	8
80	The Novel Long Noncoding RNA linc00467 Promotes Cell Survival but Is Down-Regulated by N-Myc. PLoS ONE, 2014, 9, e88112.	1.1	62
81	The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. Oncotarget, 2014, 5, 1793-1804.	0.8	105
82	Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget, 2014, 5, 4257-4268.	0.8	25
83	Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2 β via AKT in prostate cancer cells. Oncotarget, 2014, 5, 6289-6299.	0.8	22
84	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 2014, 5, 10127-10139.	0.8	31
85	Abstract 5005: The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. , 2014, , .		0
86	Abstract 1378: The histone methyltransferase adaptor WDR5 is a novel cofactor in neuroblastoma. , 2014, , .		0
87	Abstract 5138: Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. , 2014, , .		0
88	Abstract 3103: IGF2BP1 and MYCN cooperate in an oncogenic feedback loop, in high-risk neuroblastoma. , 2014, , .		0
89	Abstract 1403: TRIM16 inhibits cell growth through direct interaction and modulation of TDP43 protein stability in cancer cells. , 2014, , .		0
90	Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death and Disease, 2013, 4, e655-e655.	2.7	37

#	ARTICLE	IF	CITATIONS
91	The histone deacetylase SIRT2 stabilizes Myc oncoproteins. <i>Cell Death and Differentiation</i> , 2013, 20, 503-514.	5.0	171
92	Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. <i>Oncogene</i> , 2013, 32, 3616-3626.	2.6	60
93	Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 2357-2367.	0.4	59
94	Up-regulation of Survivin during Immortalization of Human Myofibroblasts Is Linked to Repression of Tumor Suppressor p16INK4a Protein and Confers Resistance to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2013, 288, 12032-12041.	1.6	7
95	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. <i>Nature Communications</i> , 2013, 4, 1508.	5.8	67
96	FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. <i>Leukemia</i> , 2013, 27, 1053-1062.	3.3	38
97	Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis. <i>Frontiers in Genetics</i> , 2013, 4, 80.	1.1	74
98	Abstract 3876: TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma.. , 2013, , .		1
99	Abstract 5043: The facilitates chromatin transcription (FACT) protein complex promotes neuroblastoma tumor initiation.. , 2013, , .		0
100	Abstract 2985: The histone demethylase JMJD1A induces neuroblastoma cell migration and invasion.. , 2013, , .		0
101	Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. <i>Cell Death and Disease</i> , 2012, 3, e337-e337.	2.7	34
102	Amide-based derivatives of β -alanine hydroxamic acid as histone deacetylase inhibitors: Attenuation of potency through resonance effects. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6200-6204.	1.0	7
103	Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase. <i>European Journal of Cancer</i> , 2012, 48, 3278-3287.	1.3	15
104	Abstract 2196: Upregulation of survivin during immortalization is linked to repression of p16INK4a and confers resistance to oxidative stress. , 2012, , .		0
105	DOSim: An R package for similarity between diseases based on Disease Ontology. <i>BMC Bioinformatics</i> , 2011, 12, 266.	1.2	88
106	SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability. <i>PLoS Genetics</i> , 2011, 7, e1002135.	1.5	136
107	Opposing Effects of Two Tissue Transglutaminase Protein Isoforms in Neuroblastoma Cell Differentiation. <i>Journal of Biological Chemistry</i> , 2010, 285, 3561-3567.	1.6	43
108	MYCN oncoprotein targets and their therapeutic potential. <i>Cancer Letters</i> , 2010, 293, 144-157.	3.2	92

#	ARTICLE	IF	CITATIONS
109	The cyclin-dependent kinase inhibitor, p21 WAF1 , promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. <i>Carcinogenesis</i> , 2009, 30, 1865-1871.	1.3	23
110	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. <i>European Journal of Cancer</i> , 2009, 45, 1846-1854.	1.3	40
111	The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer. <i>Cancer Research</i> , 2009, 69, 1702-1705.	0.4	360
112	Model-based Analysis of CHIP-Seq (MACS). <i>Genome Biology</i> , 2008, 9, R137.	13.9	13,517
113	Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18682-18687.	3.3	96
114	Enhancing the anti-angiogenic action of histone deacetylase inhibitors. <i>Molecular Cancer</i> , 2007, 6, 68.	7.9	24
115	Histone deacetylase inhibitors: Multifunctional anticancer agents. <i>Cancer Treatment Reviews</i> , 2006, 32, 157-165.	3.4	212
116	The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome. <i>Cancer Research</i> , 2005, 65, 2330-2336.	0.4	129
117	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3410-3415.	3.3	425
118	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. <i>Lancet</i> , The, 2002, 359, 2159-2163.	6.3	235
119	ATP P2X receptors play little role in the maintenance of neuropathic hyperalgesia. <i>NeuroReport</i> , 2000, 11, 1669-1672.	0.6	19
120	Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. <i>Pain</i> , 2000, 86, 25-32.	2.0	217
121	Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. <i>Pain</i> , 1999, 79, 31-37.	2.0	122
122	Zinc alleviates thermal hyperalgesia due to partial nerve injury. <i>NeuroReport</i> , 1999, 10, 1619-1623.	0.6	18
123	Neuroblastoma: A Malignancy Due to Cell Differentiation Block. , 0, , .		3